- Home
- URGN vs NAMI Comparison
URGN vs NAMI Comparison
Compare URGN & NAMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- NAMI
- Stock Information
- Founded
- URGN 2004
- NAMI 2014
- Country
- URGN United States
- NAMI China
- Employees
- URGN N/A
- NAMI N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- NAMI
- Sector
- URGN Health Care
- NAMI
- Exchange
- URGN Nasdaq
- NAMI NYSE
- Market Cap
- URGN 181.2M
- NAMI 185.3M
- IPO Year
- URGN 2017
- NAMI 2024
- Fundamental
- Price
- URGN $14.82
- NAMI $1.10
- Analyst Decision
- URGN Strong Buy
- NAMI
- Analyst Count
- URGN 9
- NAMI 0
- Target Price
- URGN $26.81
- NAMI N/A
- AVG Volume (30 Days)
- URGN 5.9M
- NAMI 280.0K
- Earning Date
- URGN 08-12-2025
- NAMI 08-11-2025
- Dividend Yield
- URGN N/A
- NAMI N/A
- EPS Growth
- URGN N/A
- NAMI N/A
- EPS
- URGN N/A
- NAMI 0.10
- Revenue
- URGN $91,871,000.00
- NAMI $55,677,960.00
- Revenue This Year
- URGN $36.65
- NAMI N/A
- Revenue Next Year
- URGN $88.35
- NAMI N/A
- P/E Ratio
- URGN N/A
- NAMI $11.56
- Revenue Growth
- URGN 8.98
- NAMI 7.00
- 52 Week Low
- URGN $3.42
- NAMI $1.06
- 52 Week High
- URGN $18.15
- NAMI $7.75
- Technical
- Relative Strength Index (RSI)
- URGN 73.80
- NAMI N/A
- Support Level
- URGN $6.92
- NAMI N/A
- Resistance Level
- URGN $15.22
- NAMI N/A
- Average True Range (ATR)
- URGN 1.57
- NAMI 0.00
- MACD
- URGN 1.17
- NAMI 0.00
- Stochastic Oscillator
- URGN 96.49
- NAMI 0.00
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About NAMI JINXIN TECHNOLOGY HOLDING COMPANY SPONSORED ADS EACH REP 18 ORD SHS
Jinxin Technology Holding Co is a company which operates through its subsidiaries are principally engaged in provision of digital textbook subscription services in the People's Republic of China. The company generates revenue by selling its content to hardware manufacturers in China whereby are allowed to install the company's digital educational content on the manufacturers' devices for sale to end users.